Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varizost
- Development stage
- Unknown
- Lead developer
- Incepta Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Varizost is a live, attenuated vaccine developed and manufactured by Incepta Vaccines for the prevention of varicella (chickenpox). The vaccine consists of a lyophilized preparation of the Oka strain of the varicella-zoster virus (VZV), which is produced through propagation in human diploid (MRC-5) cell cultures. It is indicated for active immunization in individuals aged 12 months and older, typically administered in a two-dose schedule. By introducing a weakened form of the virus, Varizost stimulates the host's immune system to produce active immunity against subsequent VZV infection.
- Brand names
- Varizost
- Other names
- Varicella Virus Vaccine (Live Attenuated OKA Strain)
Beyond the preview
Go deeper on Varizost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Varizost.